In-vitro activity of Ro-15-8074, a new oral cephalosporin.
The in-vitro activity of Ro-15-8074, a new oral cephalosporin, was tested against common clinical isolates, and compared with the in-vitro activity of cefaclor, cefadroxil, ampicillin and co-trimoxazole. Its activity against Enterobacteriaceae was better than those of the other antibiotics tested. It was also highly active against Haemophilus influenzae, including beta-lactamase producing strains. Its activity against Pseudomonas aeruginosa and Acinetobacter spp., was poor. Ro-15-8074 was less active against staphylococci and group D streptococci than were cefaclor, cefadroxil and ampicillin. It was equally or less active than cefaclor, cefadroxil, ampicillin and co-trimoxazole against other streptococci.
D000667:Ampicillin / Q000494:pharmacology; D001419:Bacteria / Q000187:drug effects*; D002433:Cefaclor / Q000494:pharmacology; D002434:Cefadroxil / Q000494:pharmacology; D015296:Ceftizoxime / Q000031:analogs & derivatives*; D002511:Cephalosporins / Q000494:pharmacology*; D004338:Drug Combinations / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D013420:Sulfamethoxazole / Q000494:pharmacology; D014295:Trimethoprim / Q000494:pharmacology; D015662:Trimethoprim, Sulfamethoxazole Drug Combination
D002511:Cephalosporins; D004338:Drug Combinations; D002434:Cefadroxil; C047444:cefetamet; D002433:Cefaclor; D000667:Ampicillin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D015296:Ceftizoxime; D013420:Sulfamethoxazole